Molecular Insight Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (3/A)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2008 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

FRANK DANIEL

2. Date of Event Requiring Statement (MM/DD/YYYY) 2/1/2007

3. Issuer Name and Ticker or Trading Symbol

Molecular Insight Pharmaceuticals, Inc. [MIPI]

(Last) (First) (Middle)

C/O CERBERUS CAPITAL MANAGEMENT, L.P., 299 PARK AVENUE, 22ND FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

NEW YORK, NY 10171

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

2/1/2007

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	1/1/2007 ⁽¹⁾	5/9/2016	Common Stock, par value $0.01 per share	8333	$4.800 ⁽²⁾	D ⁽³⁾

Explanation of Responses:
( 1)	This date was incorrectly reported on the Form 3 filed February 1, 2007. Effective May 9, 2006, Mr. Frank was granted a Non-Qualified Stock Option (the "Option") to buy 8,333 shares of the Company's stock at $4.80 per share. Of the 8,333 shares, 4,167 fully vested on January 1, 2007. The remaining 4,166 shares will become fully vested on January 1, 2008. The Option expires on May 9, 2016.
( 2)	This price was incorrectly reported on the Form 3 filed February 1, 2007.
( 3)	Daniel Frank is a director of Molecular Insight Pharmaceuticals, Inc. (the "Company"). Mr. Frank is a Managing Director of Cerberus Capital Management, L.P., an affiliate of which, Cerberus Partners, L.P., owns certain securities of the Company, all of which are subject to the sole voting and investment authority of Stephen Feinberg. Mr. Feinberg, in his capacity as the holder of sole voting and investment authority of more than 10.0% of the Shares pursuant to Reg. 13d-3, separately files statements pursuant to Sections 13 and 16 of the Securities Exchange Act of 1934, as amended. Mr. Frank does not exercise any voting, investment or other authority with respect to the Shares separately reported by Mr. Feinberg and he disclaims beneficial ownership thereof.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
FRANK DANIEL C/O CERBERUS CAPITAL MANAGEMENT, L.P. 299 PARK AVENUE, 22ND FLOOR NEW YORK, NY 10171	X

Signatures
/s/ Daniel Frank		11/30/2007
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.